Cytotoxic activity of 3,6-dihydroxyflavone in human cervical cancer cells and its therapeutic effect on c-jun N-terminal kinase inhibition

Molecules

Volumn 19, Issue 9, 2014, Pages 13200-13211

  Lee, Eunjung ^a   Jeong, Ki Woong ^a   Jnawali, Hum Nath ^a   Shin, Areum ^a   Heo, Yong Seok ^a   Kim, Yangmee ^a  

^a Konkuk University   (South Korea)

Author keywords

3,6 dihydroxyflavone; Anticancer effect; Binding model; Kinase; Western blotting

Indexed keywords

3,6-DIHYDROXYFLAVONE; FLAVONOID; STRESS ACTIVATED PROTEIN KINASE; TUMOR PROTEIN;

ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CHEMISTRY; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HYDROGEN BOND; PATHOLOGY; PHOSPHORYLATION; UTERINE CERVICAL NEOPLASMS;

FEMALE; FLAVONOIDS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROGEN BONDING; JNK MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM PROTEINS; PHOSPHORYLATION; UTERINE CERVICAL NEOPLASMS;

EID: 84908140933     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules190913200     Document Type: Article

References (36)

1. Sasco, A. J.; Secretan, M. B., Straif, K. Tobacco smoking and cancer: A brief review of recent epidemiological evidence. Lung Cancer 2004, 45, S3-S9.
2. Kushi, L. H.; Byers, T.; Doyle, C.; Bandera, E. V.; McCullough, M.; McTiernan, A.; Gansler, T.; Andrews, K. S.; Thun, M. J. American cancer society guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA-Cancer J. Clin. 2006, 56, 254-281.
3. Anand, P.; Kunnumakara, A. B.; Sundaram, C.; Harikumar, K. B.; Tharakan, S. T.; Lai, O. S.; Sung, B.; Aggarwal, B. B. Cancer is a preventable disease that requires major lifestyle changes. Pharm. Res. 2008, 25, 2097-2116.
4. Ernst, P. B.; Gold, B. D. The disease spectrum of Helicobacter pylori: The immunopathogenesis of gastroduodenal ulcer and gastric cancer. Annu. Rev. Microbiol. 2000, 54, 615-640.
5. Flossmann, E.; Rothwell, P. M. Effect of aspirin on long-term risk of colorectal cancer: Consistent evidence from randomized and observational studies. Lancet 2007, 369, 1603-1613.
6. Wiseman, B. S.; Werb, Z. Stromal effects on mammary gland development and breast cancer. Science 2002, 296, 1046-1049.
7. Augsten, M. Cancer-associated fibroblasts as another polarized cell type of the tumor microenvironment. Front. Oncol. 2014, 4, 1-8.
8. De Visser, K. E.; Eichten, A.; Coussens, L. M. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 2006, 6, 24-37.
9. Dobrovolskaia, M. A.; Vogel, S. N. Toll receptors, CD14, and macrophage activation and deactivation by LPS. Microbes Infect. 2002, 4, 903-913.
10. Weston, C. R.; Davis, R. J. The JNK signal transduction pathway. Curr. Opin. Genet. Dev. 2002, 12, 14-21.
11. Kennedy, N. J.; Davis, R. J. Role of JNK in tumor development. Cell Cycle 2003, 2, 199-201.
12. Kennedy, N. J.; Sluss, H. K.; Jones, S. N.; Bar-Sagi, D.; Flavell, R. A.; Davis, R. J. Suppression of ras-stimulated transformation by the JNK signal transduction pathway. Genes Dev. 2003, 17, 629-637.
13. Sharma, S. V.; Gajowniczek, P.; Way, I.; Lee, D.; Jiang, J.; Yuza, Y.; Classon, M.; Haber, D. A.; Settleman, J. A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 2006, 10, 425-435.
14. Polier, S.; Samant, R. S.; Claeke, P. A.; Workamn, P.; Prodromou, C.; Pearl, L. H. ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system. Nat. Chem. Biol. 2013, 9, 307-312.
15. Middleton, E.; Kandaswami, C.; Theoharides, T. C. The effects of plant flavonoids on mammalian cells: Implications for inflammation, heart disease, and cancer. Pharmacol. Rev. 2000, 52, 673-751.
16. Hari, K. N.; Kesava, V. K. R.; Ravikumar, A.; Supriya, M.; Ram, C.; Stanley, A. S. Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin. Diagn. Lab. Immunol. 2004, 11, 63-69.
17. Cunningham, B. D.; Threadgill, M. D.; Groundwater, P. W.; Dale, I. L.; Hickman, J. A. Synthesis and biological evaluation of a series of flavones designed as inhibitors of protein tyrosine kinases. Anti-Cancer Drug Des. 1992, 7, 365-384.
18. Kim, O. K.; Murakami, A.; Nakamura, Y.; Ohigashi, H. Screening of edible Japanese plants for nitric oxide generation inhibitory activities in RAW264.7 cells. Cancer Lett. 1998, 125, 199-207.
19. Lee, E.; Shin, S.; Kim, J.-K.; Woo, E.-R.; Kim, Y. Anti-inflammatory effects of amentoflavone on modulation of signal pathway in LPS-stimulated RAW264.7 cells. Bull. Korean Chem. Soc. 2012, 33, 2878-2882.
20. Lee, J.-Y.; Kim, J.-K.; Cho, M.-C.; Shin, S.; Yoon, D.-Y.; Heo, Y. S.; Kim, Y. Cytotoxic flavonoids as agonists of peroxisome proliferator-activated receptor γ on human cervical and prostate cancer cells. J. Nat. Prod. 2010, 73, 1261-1265.
21. Chang, H.; Lin, H.; Yi, L.; Zhu, J.; Zhou, Y.; Mi, M.; Zhang, Q. 3, 6-Dihydroxyflavone induces apotosis in leukemia HL-60 cell via reactive oxygen species-mediated p38 MAPK/JNK pathway. Eur. J. Pharmacol. 2010, 648, 31-38.
22. Karin, M. Nuclear factor-κB in cancer development and progression. Nature 2006, 441, 431-436.
23. Grivennikov, S.; Karin, M. Autocrine IL-6 signaling: A key event in tumorigenesis? Cancer Cell 2008, 13, 7-9.
24. Williams, C. S.; Mann, M.; Dubois, R. N. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999, 18, 7908-7916.
25. Heo, Y.-S.; Kim, S.-K.; Seo, C. I.; Kim, Y. K.; Sung, B.-J.; Lee, H. S.; Lee, J. I.; Park, S.-Y.; Kim, J. H.; Hwang, K. Y.; et al. Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125. EMBO J. 2004, 23, 2185-2195.
26. Baek, S.; Kang, N. J.; Popowicz, G. M.; Arciniega, M.; Jung, S. K.; Byun, S.; Song, N. R.; Heo, Y.-S.; Kim, B. Y.; Lee, H. J.; et al. Structural and functional analysis of the natural JNK1 inhibitor quercetagetin. J. Mol. Biol. 2013, 425, 411-423.
27. Jnawali, H. N.; Lee, E.; Jeong, K.-W.; Shin, A.; Heo, Y.-S.; Kim, Y. Anti-inflammatory activity of rhamnetin and a model of its binding to c-Jun. NH2-terminal kinase 1 and p38 MAPK. J. Nat. Prod. 2014, 77, 258-263.
28. Scudiero, D. A.; Shoemaker, R. H.; Paull, K. D.; Monks, A.; Tierney, S.; Nofziger, T. H.; Currens, M. J.; Seniff, D.; Boyd, M. R. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 1988, 48, 4827-4833.
29. Kim, J.-K.; Lee, E.; Shin, S.; Jeong, K.-W.; Lee, J.-Y.; Bae, S.-Y.; Kim, S.-H.; Lee, J.; Kim, S. R.; Lee, D. G.; et al. Structure and function of papiliocin with antimicrobial and anti-inflammatory activities isolated from the swallowtail butterfly, Papilio xuthus. J. Biol. Chem. 2011, 286, 41296-41311.
30. Lee, E.; Kim, J.-K.; Shin, S.; Jeong, K.-W.; Shin, A.; Lee, J.; Lee, D. G.; Hwang, J.-S.; Kim, Y. Insight into the antimicrobial activities of coprisin isolated from the dung beetle, Copris tripartitus, revealed by structure-activity relationships. Biochim. Biophys. Acta Biomembranes 2013, 1828, 271-283.
31. Waetzig, V.; Herdegen, T. Context-specific inhibition of JNKs: Overcoming the dilemma of protection and damage. Br. J. Pharmacol. 2005, 26, 455-461.
32. Tang, J.; Luan, F.; Chen, X. Binding analysis of glycyrrhetinic acid to human serum albumin: fluorescence spectroscopy, FTIR, and molecular modeling. Bioorg. Med. Chem. 2006, 14, 3210-3217.
33. Vieth, M.; Hirst, J. D.; Dominy, B. N.; Daigler, H.; Brooks, C. L. Assessing search strategies for flexible docking. J. Comput. Chem. 1998, 19, 1623-1631.
34. Suh, Y.; Afaq, F.; Johnson, J. J.; Mukhtar, H. A plant flavonoid fisetin induces apoptosis in colon cancer cells by inhibition of COX2 and Wnt/EGFR/NF-κB-signaling pathways. Carcinogenesis 2009, 30, 300-307.
35. Li, Y.; Ma, C.; Qian, M.; Wen, Z.; Jing, H.; Qian, D. Butein induces cell apoptosis and inhibition of cyclooxygenase-2 expression in A549 lung cancer cells. Mol. Med. Rep. 2014, 9, 763-767.
36. Cheong, E.; Ivory, K.; Doleman, J.; Parker, M. L.; Rhodes, M.; Johnson, I. T. Synthetic and naturally occurring COX-2 inhibitors suppress proliferation in a human oesophageal adenocarcinoma cell line (OE33) by inducing apoptosis and cell cycle arrest. Carcinogenesis 2004, 25, 1945-1952.